Novartis Ag (NVS) Cash & Equivalents Growth (1y) (2010 - 2025)
Novartis Ag (NVS) Cash & Equivalents Growth (1y) (2010 - 2025) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash & Equiv. Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
70.76% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-43.63% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
81.47% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
44.55% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-38.27% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
36.64% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
-3.76% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
19.09% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Biogen |
30.87 Bn |
26.59 Bn |
1.82 Bn |
30.19% |
| Date | Value |
|---|
| Dec 31, 2025 |
965.70% |
| Jun 30, 2025 |
-15.78% |
| Dec 31, 2024 |
-98.19% |
| Sep 30, 2024 |
-63.58% |
| Jun 30, 2024 |
-27.40% |
| Dec 31, 2023 |
78.17% |
| Sep 30, 2023 |
836.36% |
| Jun 30, 2023 |
12,330.34% |
| Dec 31, 2022 |
-39.41% |
| Sep 30, 2022 |
-780.00% |
| Jun 30, 2022 |
-1,583.33% |
| Mar 31, 2022 |
1,266.67% |
| Dec 31, 2021 |
28.46% |
| Sep 30, 2021 |
-113.16% |
| Jun 30, 2021 |
107.89% |
| Mar 31, 2021 |
-107.89% |
| Dec 31, 2020 |
-13.08% |
| Jun 30, 2020 |
-100.76% |
| Mar 31, 2020 |
-84.77% |
| Dec 31, 2019 |
-16.27% |
